辩论:手术作为微小泌乳素瘤的初始治疗
本文以社论形式辩论手术能否作为微小泌乳素瘤的一线治疗。泌乳素瘤约占激素分泌性垂体腺瘤的50%,其中超过70%为微小泌乳素瘤;多巴胺激动剂可使近90%患者泌乳素正常化并缩小肿瘤,而内镜经蝶手术在多数系列中缓解率为80%至95%以上。
要点
- 多巴胺激动剂可使近90%患者泌乳素正常化并缩小肿瘤
- 内镜经蝶手术治疗微小泌乳素瘤缓解率可达80%至95%以上
核心结论
- 社论围绕手术作为微小泌乳素瘤一线治疗的利弊展开辩论,由内分泌专家与垂体外科医生分别陈述反对与支持手术的观点。
研究设计与样本
- 本文为社论(debate)形式,未报告系统检索范围或样本量。
主要发现
- 泌乳素瘤约占激素分泌性垂体腺瘤的50%,其中超过70%为微小泌乳素瘤。
- 多巴胺激动剂高效,近90%患者可观察到泌乳素正常化与肿瘤缩小。
- 内镜经蝶手术治疗微小泌乳素瘤在多数系列中缓解率为80%至95%或更高,长期缓解率通常为75%。
- 经验丰富的垂体外科医生操作时经蝶手术并发症低于1%、死亡率为0%。
关键数值与推荐
- 内镜经蝶手术治疗微小泌乳素瘤缓解率80%至95%以上,长期缓解率通常为75%;并发症低于1%,死亡率为0%。
- 卡麦角林治疗费用较低,但长期费用差异不显著。
临床怎么用
- 临床决策需权衡多巴胺激动剂的疗效、副作用、耐药与依从性,以及经蝶手术的缓解率与安全性。
局限性
- 本文为社论,未报告原始研究的设计细节、样本量与统计比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prolactinomas are the most frequent subtype of hormone-secreting pituitary adenomas, comprising about 50%, of which more than 70% are microprolactinomas. Treatment with oral dopamine agonists (DAs) has been the mainstay of treatment for macroprolactinoma for many decades, with cabergoline being the drug of choice in most instances. DAs are highly effective; prolactin normalization and tumor shrinkage are observed in close to 90% of patients. Twenty-five percent of patients can be withdrawn from cabergoline after 2 years of treatment. However, medication side effects, the need for longer-term therapy in most patients, dopamine resistance, or poor compliance affect overall utility. Endoscopic transsphenoidal surgery (TSS) using modern methods has a similarly high success rate in treating microprolactinomas, with surgical remission rates of 80% to 95% or more reported in many series. Long-term remission rates of 75% are generally observed. In the hands of experienced pituitary surgeons, TSS is very safe, with morbidities at less than 1% and mortality rates of 0%. Cost-wise, cabergoline therapy is less expensive, although the long-term differences in cost are not substantial. The goal of this editorial is to debate the pros and cons of surgery as a first-line option for the treatment of macroprolactinoma, presenting the views of an expert endocrinologist and pituitary surgeon both against and in favor of surgery.
引用
- Molitch ME, Mamelak AN. Debate: Surgery as Initial Therapy for Microprolactinoma. J Clin Endocrinol Metab. 2025. PMID: 41032258. doi:10.1210/clinem/dgaf434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。